Research programme: serotonin 4 receptor antagonists - AngeliniAlternative Names: AF3473
Latest Information Update: 25 Jul 2011
At a glance
- Originator Angelini Group
- Mechanism of Action Serotonin 4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 25 Jul 2011 Preclinical development is ongoing in Italy
- 08 Apr 2008 Preclinical trials in Neuropathic pain in Italy (unspecified route)